Bandingkan Harga & Kinerja Indonesian Paradise Property Tbk (INPP) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Indonesian Paradise Property Tbk dan Organon Pharma Indonesia Tbk.: Indonesian Paradise Property Tbk diperdagangkan di Rp750 (kapitalisasi pasar 8,39 T, volume 24 jam 14,9 rb), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Indonesian Paradise Property Tbk jauh lebih besar — sekitar 80,4× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| INPP | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 8,39 T | 104,4 M |
Volume | 14,9 rb | — |
Lot | 149 | — |
Perputaran | 11,04 jt | — |
Harga Rata-rata | 741,07 | — |
Nilai Transaksi | 11,04 jt | — |
Harga Ekuilibrium Indikatif | 750 | — |
Volume Ekuilibrium Indikatif | 23 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Indonesian Paradise Property Tbk
PT. Indonesia Paradise Property Tbk (the Company) was established under the name of PT Penta Karsa Lubrindo based on Notarial Deed No. 96 dated June 14, 1996 of Buntario Tigris Darmawa, NG, S.H., CN., and was amended of Rachmat Santoso, S.H., Public Notary in Jakarta. The Company is an Indonesia-based company engaged in the property sector, hotel operation, general contractor and general trading. The Company's hotel is located in Bali, Indonesia.
Selengkapnya di halaman INPP →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
